The Primacy of Public Health Considerations in Defining Poor Quality Medicines

Paul N Newton, Abdinasir A Amin, Chris Bird, Phillip Passmore, Graham Dukes, Göran Tomson, Bright Simons, Roger Bate, Philippe J Guerin and Nicholas J White

PLOS Medicine, 2011, vol. 8, issue 12, 1-5

Abstract: Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.

Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001139 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 01139&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:1001139

DOI: 10.1371/journal.pmed.1001139

Access Statistics for this article

More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().